Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Intellia Therapeutics (NASDAQ:NTLA) said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to ...

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The company’s AATD discontinuation is the right decision and ...

Evercore ISI lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps an Outperform rating on the shares after ...